| Terminated | 1 | 1 | Europe | Drug (including placebo), Standard therapy | Merck KGaA, Darmstadt, Germany | Supratentorial Newly Diagnosed Inoperable Gliobastoma | 02/13 | 02/13 | | |
NCT01276496: Weekly Doses of Cilengitide and Paclitaxel in Treating Patients With Advanced Solid Tumors That Cannot Be Removed by Surgery |
|
|
| Completed | 1 | 13 | US | Cilengitide, EMD 121974, EMD-121974, Laboratory Biomarker Analysis, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Pharmacological Study | National Cancer Institute (NCI) | Adult Solid Neoplasm, Estrogen Receptor Negative, HER2/Neu Negative, Male Breast Carcinoma, Progesterone Receptor Negative, Recurrent Breast Carcinoma, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Triple-Negative Breast Carcinoma | 03/15 | | | |
